HC Wainwright Expects Lower Earnings for Leap Therapeutics

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Equities researchers at HC Wainwright reduced their Q1 2025 EPS estimates for shares of Leap Therapeutics in a research note issued on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.38) per share for the quarter, down from their previous forecast of ($0.34). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.37) EPS.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings data on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02.

Several other analysts also recently weighed in on LPTX. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Robert W. Baird lowered shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th.

Leap Therapeutics Stock Down 4.5 %

LPTX stock opened at $0.29 on Monday. The stock has a market cap of $11.16 million, a price-to-earnings ratio of -0.15 and a beta of 0.35. Leap Therapeutics has a fifty-two week low of $0.28 and a fifty-two week high of $4.79. The business has a 50 day moving average price of $0.64 and a 200 day moving average price of $2.14.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Prosperity Wealth Management Inc. acquired a new stake in shares of Leap Therapeutics in the fourth quarter valued at approximately $63,000. HighTower Advisors LLC purchased a new stake in Leap Therapeutics in the 3rd quarter valued at $65,000. Jane Street Group LLC acquired a new stake in Leap Therapeutics during the 4th quarter worth $107,000. Dauntless Investment Group LLC purchased a new position in Leap Therapeutics during the 4th quarter worth $144,000. Finally, NewEdge Advisors LLC increased its stake in Leap Therapeutics by 1,668,066.7% in the fourth quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock valued at $144,000 after purchasing an additional 50,042 shares during the period. Institutional investors and hedge funds own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.